Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response

Background: Cladribine is a highly effective immunotherapy that is applied in two short-term courses over 2 years and reduces relapse rate and disease progression in patients with relapsing multiple sclerosis (MS). Despite the short treatment period, cladribine has a long-lasting effect on disease a...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Neurological Disorders
Main Authors:	Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl, Luisa Klotz
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-12-01
Online Access:	https://doi.org/10.1177/17562864231211077